Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Diaz N, Juarez M, Cancrini C, Heeg M, Soler-Palacín P, Payne A, Johnston GI, Helmer E, Cain D, Mann J, Yuill D, Conti F, Di Cesare S, Ehl S, Garcia-Prat M, Maccari ME, Martín-Nalda A, Martínez-Gallo M, Moshous D, Santilli V, Semeraro M, Simonetti A, Suarez F, Cavazzana M, Kracker S.
Diaz N, et al. Among authors: di cesare s.
J Immunol. 2020 Dec 1;205(11):2979-2987. doi: 10.4049/jimmunol.2000326. Epub 2020 Oct 28.
J Immunol. 2020.
PMID: 33115853
Clinical Trial.